InformationGSK2636771 is a potent, orally bioavailable and selective inhibitor ofPI3Kβwith >900-fold selectivity over PI3Kα/PI3Kγ and >10-fold over PI3Kδ. Sensitive to PTEN cell lines.In vitroGSK-2636771 shows selectively inhibitory activity in PTEN cell lines (human prostate adenocarcinoma PC-3 and breast cancer HCC70) with EC50 of 36 nM and 72 nM, respectively. GSK2636771 significantly decreases cell viability in p110β-reliant PTEN-deficient PC3 prostate and BT549 and HCC70 breast cancer cell lines, and leads to a marked decrease of AKT phosphorylation only in the control prostate and breast cancer cell lines.In vivoGSK-2636771 decreases phosphorylated protein kinase Akt (Ser473) levels in these xenograft models. GSK-2636771 (100 mg/kg) do not increase glucose/insulin levels in mice.Cell Datacell lines：MALME-3M, Colo829, Colo38, A375, SK-MEL28, and A2058 cellsConcentrations：~10 μMIncubation Time：72 hoursPowder Purity:≥99%. Specification: 10mM in DMSO Molecular Formula: C22H22F3N3O3 Molecular Weight: 433.42
- UPC:
- 12352005
- Condition:
- New
- Availability:
- 2 weeks
- Weight:
- 0.85 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- G409258-1ml
- CAS:
- 1372540-25-4
- Product Size:
- 1ml
